Monday, 13 April 2020

Molecular Modelling Market Value Chain, Factor Analysis, Region And Forecasts Till 2023

Market Scenario
Molecular modelling comprises an array of computational techniques used in creation, manipulation, and representation of the various reactions and structures of molecules. Its applications included drug discovery and development but have since extended into computational chemistry and materials science. Rising use of molecular modelling by scientists to run multiple simulations can expedite the drug development process considerably.
The global molecular modelling market share is anticipated to expand at a 15.16% CAGR from 2018 to 2023 (forecast period), according to the latest report by Market Research Future (MRFR). Investments in R&D by pharmaceutical and biotechnology companies and prevalence of chronic diseases are factors certain to spur market growth over the forecast period.
According to the Brookings Private Sector Global Health R&D Project, nearly USD 159.9 Bn has been dispensed for healthcare R&D in developed and developing regions. Out of which, the majority can be credited to pharmaceutical companies. The booming biosimilars and biologics industry is bound to propel the market demand in the coming years. But the high R&D expenditure can impede market growth.
Report Overview
The report covers the latest trends affecting the market to provide the most accurate forecasts and predictions. By correlating the historical data with key market dynamics, our analysts make highly astute projections regarding the scope of the market and its future prospects. MRFR’s report includes a thorough analysis of the global molecular modelling market segmented by product, application, end-user, and region. Trends and opportunities are highlighted coupled with the market share of companies as well as their valuation in the market. It analyzes new revenue sources for players and outlines the various strategies implemented by players.
Segment Overview
Products in the molecular modelling market include software and services. Major applications include drug discovery, drug development, and others. Drug discovery is sub-segmented into direct drug design, indirect drug design, and molecular mimicry. End-users of the market include research centers and academic institutions, pharmaceutical and biotechnology companies, and others.
The segments covered in the report are analyzed with respect to four major regions – Americas, Europe, Asia Pacific (APAC), and the Middle East and Africa (MEA), with respective country-level market sizing. The definition and advantages of “molecular modelling” is outlined in the report for a comprehensive understanding of the market. The report discusses in detail the various players and their respective strategies to enhance their value chain.
Competitive Landscape
Some of the key players in the molecular modelling market include Cresset, Acellera Ltd., Schrödinger, LLC, Optibrium, BioSolve-IT, Simulations Plus, Inc., Chemical Computing Group, Certara, L.P, OpenEye Scientific Software, Dassault Systèmes, Cambridge Crystallographic Data Centre, and others. New product launches and clinical trials are used to gauge the success of drugs. Various strategies such as acquisitions, partnerships, joint ventures, and distribution agreements are used by these players to gain a major share in the market.
The report offers comprehensive profiles on these market players and assesses their current standing in the market. Company history coupled with annual turnover, profit margins, segmental share, SWOT analysis, growth strategies, new product launches, mergers and acquisitions (M&A) activities, and latest R&D initiatives are discussed in granular detail.
Opportunity:
Countries situated near the equator have become the budding ground for many chronic diseases such as chagas, dengue, leprosy, and rabies due to problematic climactic conditions forcing these countries to employ the latest advancements into their system. Governments of developing countries have initiated education programs and projects such as the Janala Project in Bangladesh, ProjectABC in Nigeria, Tostan in Senegal, Yoza in South Africa, and BridgeIT in Tanzania, and others to create awareness regarding the conditions and healthcare IT tools.
Regional Analysis
The Americas dominates the global molecular modelling market owing to well-developed technology, increasing prevalence of the people suffering from cardiovascular diseases, and increasing government support for research & development. Furthermore, high healthcare expenditure and increasing R&D activities have fuelled the growth of the market in this region.
Europe holds the second position in the global molecular modelling market, which is followed by Asia Pacific. It is expected that the government support for research & development and availability of funds for research will drive the market. Asia Pacific is the fastest growing molecular modelling market due to the presence of rapidly growing economy, developing healthcare technology, increasing healthcare expenditure, and huge patient pool.
On the other hand, the Middle East & Africa holds the least share of the market due to limited availability of medical facilities, less availability of funds, and poor political conditions in Africa.
Posted by at No comments:

Global Drug Allergy Market Trend, Industry Overview, Competitive Analysis And Foreseen By 2023

Drug Allergy Market-Overview
Allergy is the sensitivity of immune system, which occurs when a foreign substance, harmless in nature react with the immune system. This substance is known as allergen. The common allergens are dust mist, pollen, mold, smoke and many more. According to the World Allergy Organization, approximately 30-40% of the global population is suffering from allergy. Many people are suffering from different types of allergy including seasonal allergy. Additionally, most of the people also suffer from drug allergy whose prevalence is found to be increasing across the globe. Treatment involves the use of antihistamines, corticosteroids, treatment of anaphylaxis, withdrawal of the drug, and others.
According to the American Academy of Allergy, Asthma & Immunology, about 5-10% of total American population is allergic to various medicines. Adverse reaction to various drugs or medicines is common in the U.S. population.  Some of the common medicines such as penicillin, aspirin, non-steroidal anti-inflammatory medications, anticonvulsants, chemotherapy, and monoclonal antibody therapy are more likely to trigger an allergic reaction in the patients. Increasing investment for research and introduction of new treatments are leading the market growth in this region.
Increasing awareness about various allergies, the introduction of the new treatment of products and rising demand from emerging markets drives the drug allergy market growth. New research to prevent drug allergies is another key driver for the market. The global drug allergy market is growing moderately and is expected to continue its growth over the forecast period.
According to the European Academy of Allergy and Clinical Immunology (EAACI), around 2.6% hospitalization happens due to adverse drug effects while the prevalence of drug allergy in the hospitalized patients is around 10% in the Europe.
Key Players in the Drug Allergy Market:
AstraZeneca (UK), Bayer (US), Circassia (US), HAL Allergy Group (the Netherlands), Johnson & Johnson Services, Inc. (US), MAGNA Pharmaceuticals, Inc. (US), Stallergenes Greer (UK), and others.
Key Developments:
Strategic approaches adopted help the major players in the market to sustain their growth and develop their business in various geographical areas across the globe. Agreements and collaborations, mergers and acquisitions, and new product launches are various strategies followed by the key players.  
AstraZeneca:
Founded in 1999, AstraZeneca is headquartered in Cambridge, England, is a multinational pharmaceutical and biopharmaceutical company. The company offers distinctive products in three major therapy areas that provide meaningful difference to patients includes oncology; cardiovascular and metabolic diseases; and respiratory, inflammation and autoimmunity.
  • July, 2017: AstraZeneca and Merck & Co., Inc. entered a global strategic oncology collaboration to co-develop and co-commercialise AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Lynparza is an innovative, first-in-class oral poly ADP ribose polymerase (PARP) inhibitor currently approved for BRCA-mutated ovarian cancer in multiple lines of treatment. The strategic collaboration is expected to further increase the number of treatment options available to patients.
Stallergenes Greer:
  • October, 2017: Stallergenes Greer announced the acquisition of Medic Savoure Limited, a well-established allergy immunotherapy (AIT) leader in Canada. The acquisition strengthens local presence of Stallergenes Greer as well as accelerates the company’s growth in Canada. The acquisition is also expected to increase cash flow allergy business that bolsters Stallergenes Greer’s North American operations. The company focus on expanding its business in allergy immunotherapy.
  • November, 2016: Stallergenes Greer announced a collaboration with the Sean N. Parker Center for Allergy and Asthma Research at Stanford University ("Stanford"). The main focu of collaboration is to identify potential biomarkers of Allergy Immunotherapy (AIT) efficacy. And to access the impact of peanut oral immunotherapy on biological parameters. The collaboration with the Sean N. Parker Centre for Allergy and Asthma Research at Stanford University will help to strengthen its research and development goals to determine new treatment of allergic patients.
  • July, 2014: Stallergenes Greer announced the acquisition of the entire share capital of ALERGO PHARMA S.R.L., an Argentinean allergen immunotherapy (AIT) company. This acquisition focuses on combination of two complementary dedicated allergen immunotherapy companies, to widen the range of products for diagnosis and treatment of patients suffering from allergic respiratory diseases. This acquisition establishes Stallergenes Greer among the top allergen immunotherapy pharmaceutical companies in Latin America thus expanding the company’s geographical presence.
Research by Key Payers in the Market:
HAL Allergy Group:
HAL is one of the major companies in drug allergy market, head quartered at Leiden, Netherlands.  In 1959, it was started as am small laboratory in the centre of Haarlem, the Netherlands. It products include allergy vaccines and diagnostic products. 
  • May, 2016: HAL Allergy had successfully completed a Phase I trial with its novel subcutaneous immunotherapy (SCIT) product for treatment of peanut allergy. The drug contains peanut allergens which was modified using proprietary technology to reduce their allergenicity.
Posted by at No comments:

Tendinitis Treatment Market 2019 – Leading Manufactures, Regions, Drivers, Analysis And Forecasts Till 2023

Market Scenario:
An expert on premium research reports, Market Research Future predicts that Global tendinitis treatment market is expected to grow at the CAGR of ~3.8% during the forecast period and is estimated to reach USD 426.4 million by 2023. According to a recent study report published by the Market Research Future, the global tendinitis treatment market growth is expected to gain eminence over the forecast period. The market is forecasted to demonstrate a steady growth by 2023, surpassing USD 426.4 million with a constant CAGR during the anticipated period (2017 – 2023).
Tendinitis is the inflammation of the tendon, thick cords that attach the muscles to the bone. The inflammation occurs as a result of sudden injury to the tendon, repetitive movement or disease condition such as diabetes, rheumatoid arthritis, gout, Reiter's syndrome or lupus. In case of patients with gout, the uric acid crystals appear in the tendon sheath leading to friction. Tendinitis is found to be prevalent among athletes and is one of the common sport injuries in sport players, especially tennis, golf and others. Various pharmacological and non-pharmacological treatments are available for the treatment of tendinitis. Non-steroidal anti-inflammatory drugs (NSAIDs) constitute the preliminary treatment options. Other treatments including physical therapy, rest, and occupational therapy. Surgery is the last resort for tendinitis, and is only recommended in case of severe damage to the tendon that cannot be treated using pharmacological treatment options.
Key players for Global Tendinitis Treatment Market:                                   
  • Almatica Pharma, Inc. (US),
  • AstraZeneca (US),
  • Bayer (Germany),
  • Boehringer Ingelheim Pharmaceuticals, Inc. (US),
  • Merck & Co., Inc (US),
  • Pfizer (US).
Intended Audience:
  • Tendinitis medicines manufacturers
  • Tendinitis medicines and treatment providers
  • Medical Research laboratories
  • Research and Development (R&D) Companies
  • Market Research and Consulting Service Providers
  • Potential Investors
Segments:
Global tendinitis treatment market has been segmented on the basis of condition which comprises of tennis elbow, golfer's elbow, pitcher's shoulder, swimmer's shoulder, jumper's knee, and others.
On the basis of treatments, the market has been segmented into medications, therapy, surgical repair, and others. Medication sub-segmented into pain relievers, corticosteroids, Platelet-Rich Plasma (PRP), and others. Therapy is further sub-segmented into hot and cold therapy, physical therapy, occupational therapy, and others.
On the basis of diagnosis, the market is segmented into physical exam, imaging tests, and others. Imaging test is sub-segmented into ultrasound, Magnetic Resonance Imaging (MRI) scans, and others.
On the basis of end user, it is segmented into hospitals & clinics, medical research centers, academic institutes, and others.
Regional analysis
Considering the global scenario of the market, America is the top contributor in this market. The Americas mainly includes North America and South America. Due to developed healthcare infrastructure and increasing R&D funding, US is dominating country in this region. Europe is second largest market for tendinitis treatment. Due to innovative product development and rapid adoption of new treatments, Germany is dominating this market. Asia Pacific is witnessing rapid growth in this market which is mainly due to rapidly changing healthcare sector, increasing awareness, and rising healthcare expenditure. Middle East and Africa is expected to have limited growth while Middle Eastern countries are expected to dominate this market during the forecast period.
Competitive Analysis
The market for tendinitis treatment is characterised by the presence of several well-established and small players, the global market of tendinitis treatment appears to be highly competitive and fragmented. Major players are increasingly expanding their footprint in the emerging nations, making it putting pressure on the regional players, especially in terms of features such as type, product portfolios, and pricing. The market is witnessing intensified competition which is expected to get more intensified further during the forecast period. The tendinitis treatment market appears to be highly competitive owing to the presence of several large and small key players accounting for a substantial market share. Many leading players are concentrated in the Americas owing to well-established market and high healthcare expenditures; these players have expanded their market in other region as well. Furthermore, the companies such as Abbott, AstraZeneca, Teva, and Pfizer are well-established in European market. The major four players namely Abbott, AstraZeneca, Teva, and Pfizer accounted for more than 17% share of the Americas and Europe tendinitis market.
In April 2017, Pfizer entered into a merger with Allergan to gain access for Allergan's portfolio including Botox, Viagra, the Prevnar pneumonia vaccine, and treatments for ailments including Alzheimer’s and rheumatoid arthritis.
Furthermore, in July 2017, Merck & Co.Inc & AstraZeneca entered into strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s LYNPARZA (olaparib) for multiple cancer types.   
Furthermore, in November 2016, AstraZeneca announced a licensing agreement between MedImmune, its global biologics research and development arm, and Allergan plc., for the global rights to MEDI2070.
Moreover, May 2014, the company acquired Merck & Co., Inc.’s non-prescription business to become the OTC leader in North America and Latin America & achieve top global positions in key OTC product categories.
Therefore, the growing key business strategies will help the key competitors to expand their presence in various parts of the globe for their competitive products and will has spurred the growth of the market.  
Posted by at No comments:

Worldwide Keratoconus Treatment Market 2019 Synopsis With Leading Players, Industry Growth Factor Foresight By 2023

Keratoconus treatment market information, by type (Forme Fruste keratoconus, Corneal Hydrops, and others), by diagnosis (Computerized corneal mapping, Keratometry, and others), by treatment (Lenses, Surgery, and others), by end user- global forecast till 2023
Market Scenario:
The Global Keratoconus Treatment Market has been evaluated as a rapidly growing market and it is expected to continue growing in the near future.
Approximately 3 million people are affected by this disease across the globe. Advanced diagnostic and treatment options are key drivers for this market. Increasing awareness of the disease, increasing funding for R&D and growing demand from emerging regions such as Asia are major driving forces of the market. Major players of this market are investing in R&D to develop effective solution for keratoconus. Introduction of wide range of lenses is important factor for market growth.
The market for keratoconus treatment was around USD 322.7 million in 2016 and is expected to reach USD 427.5 million by 2023 which is a projected CAGR of 4.1%.
Keratoconus KC is a condition of the eye which results in liberal thinning of the cornea. This may result in blurry vision, double vision, near sightedness, astigmatism, and light sensitivity. Usually both eyes are affected. In more severe cases a scarring or a circle may be seen within the cornea. While the cause is unknown, it is thought to occur due to a combination of genetic, environmental, and hormonal factors.
Further about seven percent of those affected have a family history of the condition, proposed environmental factors comprise of rubbing eyes and allergies. The fundamental mechanism involves changes of the cornea to a cone shape. Diagnosis is by examination with a slit lamp.
Moreover initially the condition can typically be corrected with glasses or soft contact lenses. As the disease worsens special contact lenses may be required. In most people the disease stabilizes after a few years without severe vision problems. In a small number of Keratoconus KC is a condition of the eye which results in liberal thinning of the cornea. This may result in blurry vision, double vision, near sightedness, astigmatism, and light sensitivity. Usually both eyes are affected. In more severe cases a scarring or a circle may be seen within the cornea. While the cause is unknown, it is thought to occur due to a combination of genetic, environmental, and hormonal factors.
Key Players for Global Keratoconus Treatment Market:                               
Some of the key players in this market are: Bausch & Lomb Incorporated (US), CIBA VISION (US), CooperVision (US), HOYA Vision Care (Singapore), Johnson & Johnson Vision Care, Inc. (US), Menicon Co., Ltd. (Japan), Novartis AG (Switzerland), Optik Seis (Indonesia), and SAFILENS S.R.L. (Italy), and others.
Segmentations:                                                                                                                                        
Global keratoconus treatment market has been segmented on the basis of type which comprises of forme fruste keratoconus, corneal hydrops, keratoglobus, pellucid marginal degeneration, posterior keratoconus, and others.
On the basis of end user, it is segmented into eye hospitals & clinics, medical research centers, academic institutes, and others.
On the basis of diagnosis, the market is segmented into computerized corneal mapping, keratometry, slit-lamp examination, refraction test, and others. Slit-lamp examination includes tonometry, vision testing, and others.
On the basis of treatments, the market has been segmented into lenses, surgery, collagen cross-linking, and others. Lenses is sub-segmented into eyeglasses or soft contact lenses, hard contact lenses, piggyback lenses, hybrid lenses, scleral lenses, and others. Surgery is sub-segmented into corneal inserts, cornea transplant, and others. Collagen cross-linking is still in research process and more study is required to implement this treatment option.
Regional Analysis
Considering the global scenario of the market, America is the highest revenue generator with North American region contributing the most. North America mainly includes US and Canada. US is one of the dominant markets not only in America but also in the global market. European market is the second largest and UK is believed to be the fastest growing market for keratoconus treatment in this region. Increasing awareness, growing purchasing power, and rapidly improving healthcare sector are driving the growth for Asia Pacific keratoconus market. Asia Pacific is one of the high potential market for keratoconus treatment. Due to slow adoption of new treatments and prosucts, Middle East and Africa is expected to grow at steady pace.
Posted by at No comments:

Hirsutism Treatment Market Size Estimation By Top Manufacturer, Latest Trends And Global Industry Forecast 2019 To 2023

The global hirsutism market forecast 2023 is presumed to expand at 13.6 % CAGR during the forecast period (2017-2023) owing to the rising expenditure on personal care, asserts Market Research Future (MRFR). Hirsutism is a condition where a woman faces unwanted and excessive male-pattern hair growth on her body. The unwanted hair growth is mainly found in areas such as back, face, stomach, and chest and is majorly caused due to hyperandrogenism which may be ovarian or adrenal. Some of the common symptoms include balding, deepening of voice, decreased breast size, acne, enlargement of the clitoris, and others.
Drivers and Constraints Impacting the Market
Women are nowadays getting more conscious regarding their looks which is further influencing them to opt for hirsutism treatment. Laser therapy is one the most demanding treatments among the women driving the market. With the increasing availability of treatment and products along with the increasing awareness regarding hirsutism is propelling the market growth during the assessment period. Also, growing demand from emerging economies such as South America and Asia are likely to foster the market. Moreover, hospitals are investing in technology upgradation in order to provide effective treatment to their patients which is further expanding the market growth during the review period.
On the flip side, low per capita healthcare expenditure among the low and middle-income countries and lack of awareness regarding hirsutism are some of the major factors likely to retard the market growth in the coming years. Moreover, the cost of medical laser systems is high which makes it hard to afford for every individual, thereby hampering the market growth.
Global Hirsutism Market: Segmental Analysis
The global hirsutism market has been segmented on the basis of type, diagnosis, treatment, end-user, and region.
By mode of type, the global hirsutism market has been segmented into secondary hirsutism, idiopathic hirsutism, and others.
By mode of diagnosis, the global hirsutism market has been segmented into physical examination, blood tests, imaging tests, and others. Among these, the segment for blood-test is further sub-segmented into DHEA-sulfate test, testosterone level test, and others. The physical examination segment is sub-segmented into palpation and percussion, inspection, auscultation, and others. The imaging test is sub-segmented into CT scan, ultrasound, and others.
By mode of treatment, the global hirsutism market has been segmented into procedures, medications, and others. Among these, the medications segment is sub-segmented into anti-androgens, topical cream, oral contraceptives, and others. Procedures comprise laser therapy, electrolysis, and others.
By mode of end-users, the global hirsutism market has been segmented into hospitals and clinics, academic institutes, medical research centers, and others.
Regional Insights
Geographically, the hirsutism market span across four main regions namely, Europe, America, Asia Pacific, and the Middle East and Africa.
Among all the regions, America is estimated to hold the largest market share owing to the increasing demand for treatment and technological advancements in this region. North America is considered to be the dominant region in America. The U.S. generates the highest revenue in this region.
Asia Pacific is considered to be the fastest growing region owing to increasing expenditure on healthcare, growing awareness regarding hirsutism, and availability of affordable healthcare facilities in this region.
Europe is considered to be the second largest market owing to the presence of countries such as France, Germany, and the U.K. On the other hand, the Middle East and Africa showcases the least market share and is anticipated to expand at a slower rate than the average growth rate.
Industry News
A change in the law in Western Australia has drastically reduced the price of laser hair removal. SILK Laser Clinics, which once sold a 67 % stake to the Advent Partners in a deal valuing it between $50 million and $100 million, has opened its first two clinics in WA.
Competitive Dashboard
The major players operating the global market are Bayer AG (Germany), Bristol-Myers Squibb Company (US), AbbVie Inc. (US), Allergan (Republic of Ireland), Sun Pharmaceutical Industries Ltd. (India), Jubilant Cadista (US), Pfizer Inc. (US), and others.
Posted by at No comments:
Labels:

Pediatric Brain Tumor Industry Overview By Growth Factors, Product Chain Value, Competitors Analysis And Forecast 2023

Market Research Future published Pediatric Brain Tumor Market Research Report segmented By Types (Gliomas, Mixed Neuronal-Glial Tumors, Embryonal Tumors, and others), By Diagnosis (Imaging Tests, Brain Or Spinal Cord Tumor Biopsy, and others), By Treatment, By End User and Global Forecast Till 2023
Key Players for Global Pediatric Brain Tumor Market:
Some of the key players in this market are: Abbott. (US), AbbVie Inc. (US), Akorn, Inc. (US), Agios, Inc. (US), Baxter (US) , Bayer AG (US), Epizyme, Inc. (US), Novartis AG (Switzerland), Mylan N.V. (US), and others
Pediatric brain tumor is uncontrolled or abnormal growth of normal cell in the brain in children. Brain tumors mainly are of two types, cancerous (malignant) and noncancerous (benign). It is second most common type of cancer in children and it comprise about 25% of childhood cancer.
The global pediatric brain tumor market growth to cross during the forecast period and expected to reach US$ 1659.4 million by 2023.
The cases of pediatric tumors are increasing globally that leading the growth of the market. Advanced diagnostic technology and new treatments are also major driving forces of the market. Rising healthcare infrastructure, extended insurance cover, government initiatives, and emerging economies are driving the market. Rising funding for R&D and clinical trials as well as FDA approvals are also major growth factors for global pediatric brain tumor market.
Segmentation:
Global pediatric brain tumor market has been segmented on the basis of types which comprises of gliomas, mixed neuronal-glial tumors, embryonal tumors, choroid plexus papilloma/carcinoma, non-neuroepithelial tissue tumors, meningeal tumors, and others. Gliomas is further sub-segmented into astrocytoma, malignant gliomas, and others. Mixed neuronal-glial tumors are further sub-segmented into ganglioglioma, subependymal giant cell tumor, pleomorphic xanthoastrocytoma, and others. Embryonal tumors are further sub-segmented into primitive neuroectodermal tumor (PNET), atypical teratoid/rhabdoid tumor, and others. Tumors arising from non-neuroepithelial tissue are further sub-segmented into craniopharyngioma, pineal region tumors, and others.
On the basis of diagnosis, it is segmented into physical exam, Imaging tests, brain or spinal cord tumor biopsy, Llmbar puncture (spinal tap), blood and urine tests, and others. Imaging tests are further sub-segmented into Magnetic Resonance Imaging (MRI) scan, Computed Tomography (CT) scan, Positron Emission Tomography (PET) scan, Angiogram, and others. Magnetic Resonance Imaging (MRI) scan is further sub-segmented into Magnetic Resonance Angiography (MRA), Magnetic Resonance Spectroscopy (MRS), Magnetic resonance perfusion, Functional MRI (fMRI), and others. Brain or spinal cord tumor biopsy is further sub-segmented into Stereotactic needle biopsy, Craniotomy, and other.
On the basis of treatment, the market has been segmented into surgery, therapies, drug treatment, and others. Surgery is further sub-segmented into surgical biopsy, resection (removal), Shunt placement/revision, and others. Therapies includes Radiation therapy, Chemotherapy, Targeted therapy, and others. Chemotherapy includes Carboplatin, Carmustine (BCNU), Cisplatin, Cyclophosphamide, Etoposide, Lomustine (CCNU), Methotrexate, Temozolomide, Thiotepa, Vincristine, and others. Drug treatment is further sub-segmented into Corticosteroids, Anti-seizure drugs (anti-epileptics), Hormones, and others.
On the basis of end user, it is segmented into hospitals and clinics, medical research centers, academic institutes, and others.
Posted by at No comments:
Labels:

World Intracranial Hemorrhage Diagnosis and Treatment Market Estimation Of Top Key Players Shares, Revenue, Analysis And Forecasts Till 2023

Global intracranial hemorrhage diagnosis and treatment market information; by devices (invasive and non-invasive) by types (intracranial hemorrhage, cerebral hemorrhage, and other) by drugs (anti-hypertensive, others); by surgeries - Forecast to 2023
Market Scenario:
The Global Intracranial Haemorrhage Treatment Market is chiefly driven by factors such as rising cases of trauma, accidents, age related brain disorders, cancer etc.  The critical market constraints is the invasive nature of most intra-cranial pressure monitors.
Bleeding or haemorrhages loss of blood from the circulatory system which may be internal or external due to variety of conditions such as trauma, tissue damage due to surgery, accidents, cuts etc. Generally loss of 10–15% of the total blood volume does not cause serious mental problems and can be tolerated by the body. Intracranial haemorrhaging is bleeding in the brain due to trauma or medical conditions such as cancer, tumour etc.
Considering all these factors the intracranial hemorrhage diagnosis and treatment market share is expected to reach $ 1.9 billion by the end of 2023, this market is projected to growing at a CAGR of ~ 6.1 % during 2017-2023.
Key players:
Key players profiled in the report are Medtronic Plc., Codman & Shurtleff, Inc., Raumedic AG, Vittamed, Sophysa Ltd., Orsan Medical Technologies, and Spiegelberg GmbH, Johnson & Johnson, Sophysa Ltd, HaiWeiKang, Head Sense Medical, InfraScan, Inc., Integra Life Sciences Corporation and others.
Regional analysis:
US accounts for the maximum market share due to favorable reimbursement scenario and greater expenditure on healthcare. Europe is the second largest market due to large disposable income and rising awareness. Asia pacific region will be the fastest region because of large unmet needs which will be led by China and India. The Middle East and Africa market will be led by the gulf nations particularly Saudi Arabia and UAE. The poor regions of Africa is expected to be a laggard due to poor economic and political conditions.
Segmentation:
The global intracranial hemorrhage diagnosis and treatment market is segmented on the basis of devices and types. Based on the devices, the market has been segmented as invasive and non-invasive. The invasive segment is sub-segmented into ventricular drainage pressure monitors, lumbar drainage pressure monitors, micro-transducer pressure monitors. The non-invasive segment is sub-segmented into tissue resonance analysis (TRA) and Trans Cranial Doppler (TCD). Based on the types, the market has been segmented as intracranial hemorrhage treatment, cerebral hemorrhage, subarachnoid hemorrhage, postpartum hemorrhage, pulmonary hemorrhage, and other. Based on the drugs, the market has been segmented as anti-hypertensive, coagulants, and others. Based on the surgeries, the market has been segmented as decompression surgery, craniotomy with open surgery, simple aspiration, endoscopic evacuation, stereotactic aspiration, and clipping or coiling procedures.
Posted by at No comments:
Subscribe to: Posts (Atom)